Cadrenal Therapeutics (CVKD) CEO Quang Pham Sells $11K of Stock
On June 16, 2026, CEO Quang Pham sold 3,613 shares of Cadrenal Therapeutics.
Reviewed by automated data checks against the source filing. How we make and check alerts
Quang Pham, Chairman, CEO and Interim CFO at Cadrenal Therapeutics, Inc. ($CVKD), sold 3,613 shares at an average price of $3.18, worth about $11,489.34, on June 16, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $CVKD is up 0.7% after 1 week, down 23.4% after 1 month and down 64.1% to date (from the $3.04 close on Jun 16, 2026).
CVKD
Cadrenal Therapeutics, Inc.
Key Points
- Cadrenal Therapeutics CEO Quang Pham sold 3,613 shares on June 16, 2026, for $11,489.34.
- Shares of NasdaqCM:CVKD traded at $3.50 with a market cap of $9.5 million.
- Cadrenal Therapeutics develops therapies for immune and thrombotic conditions.
Get $CVKD trade alerts by text
We text you when insiders, Congress or big funds trade $CVKD. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Cadrenal Therapeutics, Inc. alert may contain errors. Disclosures
On June 16, 2026, Quang Pham, the Chairman, CEO, and Interim CFO of Cadrenal Therapeutics, Inc. (NasdaqCM:CVKD), sold 3,613 shares of the company. The shares were sold at an average price of $3.18 each, totaling $11,489.34. This transaction was made under a pre-arranged trading plan.
Cadrenal Therapeutics, Inc. Stock Up 227.1%
Shares of Cadrenal Therapeutics, trading under the ticker CVKD on the Nasdaq Capital Market, are currently priced at $3.50. The company has a market capitalization of approximately $9.5 million. Its forward P/E ratio is not meaningful as the company is not currently profitable, with an EPS of -$5.59. The stock has a beta of 1.613, indicating higher volatility compared to the market. Over the past year, the stock's price ranged from a low of $3.02 to a high of $14.64. The 50-day moving average is $5.02, while the 200-day moving average stands at $8.50. Cadrenal maintains a current ratio of 2.68 and a quick ratio of 2.17, reflecting its ability to meet short-term obligations.
About Cadrenal Therapeutics
Cadrenal Therapeutics, Inc. is a biotechnology company based in Ponte Vedra, Florida. It focuses on developing innovative therapies for serious immune and thrombotic conditions. Among its key projects is Tecarfarin, an oral vitamin K antagonist in Phase 3 trials aimed at preventing heart attacks, strokes, and deaths due to blood clots in patients with chronic anticoagulation needs. The company is also working on CAD-1005, a 12-LOX inhibitor for treating heparin-induced thrombocytopenia, and Frunexian, a factor XIa inhibitor for hospital use. Cadrenal collaborates with Abbott Global Enterprises to evaluate Tecarfarin's efficacy and safety in patients with left-ventricular assist devices.
Bottom Line
Quang Pham's sale of shares in Cadrenal Therapeutics is part of a planned trading strategy, reflecting personal financial management rather than a direct comment on the company's outlook. Investors often track insider transactions for insights into management's view of the company's future. However, it's important to note that these transactions are reported after they occur, providing a historical perspective rather than a real-time signal.
Related Filing Alerts
Source: Quang Pham's Form 4 filing on $CVKD (Jun 16, 2026). Find the original filing: CVKD Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts